Interpreting the Results

Predict both clinical risk and tumor aggressiveness

Oncotype DX GPS is proven to be an independent predictor of both clinical risk and tumor aggressiveness after radical prostatectomy for patients with biopsy Gleason scores of 3+3, 3+4 and 4+3.1-4.

GPS animation

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report, and view sample reports .



How do you use the GPS™ report? The value of the GPS™ assay.

Dr. Scott Sellinger (Advanced Urology Institute) describes how and why he uses the GPS report in his practice.


Getting your results

Most Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Exact Sciences Laboratory. You can access the results through the online physician portal or receive the report by fax.

View Sample Reports

Start Report Guide
Start Report Guide
Start Report Guide
Start Report Guide

  1. Van Den Eeden et al. Eur Urol. 2017.
  2. Klein et al. Eur Urol. 2014.
  3. Cullen et al. Eur Urol. 2014.
  4. Cullen et al. Urology. 2020.

*Adverse pathology defined as Gleason ≥4+3 and/or pT3+.
National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.